1999 Fiscal Year Final Research Report Summary
Clinical application of angiogenic therapy for ischemic heart disease
| Project/Area Number |
10557067
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | KYOTO UNIVERSITY |
|---|
Principal Investigator |
FUJITA Masatoshi College of Medical Technology, KYOTO UNIVERSITY Professor, 医療技術短期大学部, 教授 (50190046)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASEGAWA Koji Graduate School of Medicine, KYOTO UNIVERSITY Assistant, 大学院・医学研究科, 助手 (50283594)
TABATA Yasuhiko Graduate School of Medicine, KYOTO UNIVERSITY Assistant Professor, 再生医科学研究所, 助教授 (50211371)
NOHARA Ryuji Graduate School of Medicine, KYOTO UNIVERSITY Assistant Professor, 大学院・医学研究科, 講師 (80180769)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Keywords | Angiogenic therapy / bFGF / Coronary collateral vessel / Effort angina / Heparin / Counterpulsation / Gelatin gel / Myocardial ischemia |
|---|
| Research Abstract |
Angiogenic therapy is noticed as a new treatment for ischemic heart disease, which increases blood flow to the ischemic myocardium as a result of collateral development secondary to the administration of angiogenic growth factors. While the effectiveness of this treatment is reported in several canine experiments, clinical applications have been launched out in Germany and U.S.A..
We found that significant coronary collateral development is induced by the implantation of bFGF-impregnated acidic gelatin hydrogel microspheres into the infarct myocardium of dogs with acute coronary occlusion. We also found that regional wall motion abnormality is attenuated by the treatment and this treatment is useful for the preservation of ischemic myocardium. As a future clinical application, we have a plan of angiogenic therapy with use of bFGF-impregnated acidic gelatin hydrogel microspheres for patients who are refractory to medical therapy and are not a candidate for percutaneous or surgical revascularization.
EECP (enhanced external counterpulsation) as well as IABP (intra-aortic balloon pumping) increases the aortic diastolic pressure, and decreases the aortic systolic pressure resulting in the augmentation of coronary blood flow and cardiac output. We reported that 35 hours of EECP with the 5,000 U of heparin pretreatment alleviated anginal attack in a patient with effort angina. It is conceivable that EECP combined with heparin pretreatment has great potential as noninvasive treatment of angina patients.
|
